| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | James Wilson | Q16947166 |
| P2093 | author name string | Lauren E Mays | |
| P2860 | cites work | Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 |
| Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors | Q24673796 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES | Q28202390 | ||
| Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 | Q28290118 | ||
| Toll-like receptors: critical proteins linking innate and acquired immunity | Q29615190 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. | Q31934596 | ||
| Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity | Q33490137 | ||
| Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease | Q33637062 | ||
| Cloning and characterization of adeno-associated virus type 5. | Q33641228 | ||
| Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. | Q33781976 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure | Q33786029 | ||
| CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells | Q33810726 | ||
| BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver | Q33822204 | ||
| Danger signals: SOS to the immune system | Q33931055 | ||
| AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells | Q33931609 | ||
| Inflammatory cytokines as a third signal for T cell activation | Q33936084 | ||
| Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. | Q34025098 | ||
| Clades of Adeno-associated viruses are widely disseminated in human tissues. | Q34193756 | ||
| Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein | Q34371678 | ||
| Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells | Q34574858 | ||
| Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. | Q34595095 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
| Adeno-associated virus vectors for therapeutic gene transfer | Q35052563 | ||
| Association of 20-Millimicron Particles with Adenoviruses. | Q35164906 | ||
| Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells | Q35186003 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model | Q35847459 | ||
| Systemic protein delivery by muscle-gene transfer is limited by a local immune response | Q35847626 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. | Q35892008 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. | Q36007714 | ||
| Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice | Q36144935 | ||
| Heterogeneity and plasticity of T helper cells | Q36388771 | ||
| Tr1 cells: from discovery to their clinical application. | Q36390028 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance | Q36492202 | ||
| Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector | Q36663364 | ||
| Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness | Q36825024 | ||
| Toll-like receptors impact on safety and efficacy of gene transfer vectors | Q36841516 | ||
| Maintaining immunological tolerance with Foxp3. | Q36965687 | ||
| Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy | Q37066228 | ||
| The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice | Q37286686 | ||
| Peripheral tolerance in CD8+ T cells | Q37408571 | ||
| Dendritic cell modulation as a new interventional approach for the treatment of asthma | Q37657148 | ||
| Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer | Q39302902 | ||
| Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. | Q39303013 | ||
| Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. | Q39501844 | ||
| Adeno-associated virus as a vector for liver-directed gene therapy. | Q39583470 | ||
| Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors | Q39601191 | ||
| Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D | Q39881602 | ||
| Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery | Q40583540 | ||
| Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. | Q40863195 | ||
| Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration | Q40940810 | ||
| Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. | Q41190212 | ||
| Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver | Q41753510 | ||
| Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 | ||
| Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. | Q41972673 | ||
| Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation | Q42063190 | ||
| Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice | Q42121728 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Liposome-mediated gene transfer into human vascular smooth muscle cells | Q42802949 | ||
| Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice | Q44678756 | ||
| AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. | Q44753961 | ||
| Humoral and cellular immunity to an encoded protein induced by direct DNA injection | Q44806502 | ||
| Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. | Q44937538 | ||
| Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 | ||
| Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins | Q45384856 | ||
| The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver | Q45396033 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy | Q45409051 | ||
| Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques | Q45731350 | ||
| Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina | Q45760694 | ||
| Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products | Q45868913 | ||
| Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. | Q45869966 | ||
| Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer | Q45874902 | ||
| Major role of local immune responses in antibody formation to factor IX in AAV gene transfer | Q45883516 | ||
| Gene therapy -- promises, problems and prospects | Q45883584 | ||
| Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
| Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors | Q45886179 | ||
| Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 | ||
| CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. | Q46028085 | ||
| Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver | Q48004746 | ||
| Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. | Q51975070 | ||
| Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells | Q58882233 | ||
| Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells | Q77291206 | ||
| Immunogenic versus tolerogenic dendritic cells: a matter of maturation | Q84001593 | ||
| Introduction: the role of innate immunity in the adaptive immune response | Q95440614 | ||
| P433 | issue | 1 | |
| P921 | main subject | T cell activation | Q14863969 |
| P304 | page(s) | 16-27 | |
| P577 | publication date | 2010-11-30 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | The complex and evolving story of T cell activation to AAV vector-encoded transgene products | |
| P478 | volume | 19 |
| Q34814931 | A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer |
| Q37731772 | A multifunctional AAV-CRISPR-Cas9 and its host response |
| Q34669335 | A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression |
| Q39409371 | Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. |
| Q35599302 | Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells |
| Q36838524 | Adeno-associated virus-coated allografts: a novel approach for cranioplasty |
| Q28073994 | Advances in gene therapy for muscular dystrophies |
| Q33799315 | Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection |
| Q58695649 | Cas9 immunity creates challenges for CRISPR gene editing therapies |
| Q36401337 | Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community |
| Q64977765 | Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. |
| Q40358542 | Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency. |
| Q39394803 | Complexity of immune responses to AAV transgene products - Example of factor IX. |
| Q38959186 | Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery |
| Q42271911 | Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors |
| Q34177586 | Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice. |
| Q33832987 | Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: preliminary studies |
| Q92547654 | Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity |
| Q38854575 | Engineering AAV receptor footprints for gene therapy |
| Q35174932 | Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. |
| Q91938979 | Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity |
| Q37972689 | Foxp3(+) regulatory T cells, immune stimulation and host defence against infection |
| Q33782799 | Full-length dystrophin reconstitution with adeno-associated viral vectors |
| Q36295934 | Gene Therapy for Duchenne muscular dystrophy |
| Q34566454 | Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors |
| Q36147475 | Gene therapy approaches for lysosomal storage disease: next-generation treatment |
| Q27007012 | Gene therapy on the move |
| Q37043485 | Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector |
| Q36290952 | Genome editing for inborn errors of metabolism: advancing towards the clinic. |
| Q31120301 | Glial promoter selectivity following AAV-delivery to the immature brain |
| Q28482901 | Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling |
| Q38287263 | Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy |
| Q92093599 | Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q35988683 | Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease |
| Q35451204 | Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. |
| Q92301725 | Innate Immune Response Following AAV Administration |
| Q37939843 | Innate Immune Responses to AAV Vectors |
| Q40117829 | Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs. |
| Q35399100 | Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer. |
| Q36547398 | Liquid jet delivery method featuring S100A1 gene therapy in the rodent model following acute myocardial infarction |
| Q39553052 | Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia |
| Q91636324 | Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV |
| Q38544793 | Lung gene therapy-How to capture illumination from the light already present in the tunnel |
| Q64097789 | Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes |
| Q99559616 | Nanochannel-Based Poration Drives Benign and Effective Nonviral Gene Delivery to Peripheral Nerve Tissue |
| Q40153269 | Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study |
| Q40097321 | Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer |
| Q36659250 | Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. |
| Q36582796 | Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector |
| Q28276617 | Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA) |
| Q35726773 | Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome |
| Q91904925 | Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q35078590 | Recombinant AAV-directed gene therapy for type I glycogen storage diseases |
| Q40814049 | Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs. |
| Q38168940 | Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®). |
| Q57039821 | Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| Q52431127 | Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies. |
| Q26767363 | Targeted approaches to induce immune tolerance for Pompe disease therapy |
| Q33902499 | The potential of adeno-associated viral vectors for gene delivery to muscle tissue |
| Q37503995 | The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. |
| Q30541192 | Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy. |
| Q38226671 | Virus expression vectors |
Search more.